CAS: 2409963-83-1; (Z)-3-Fluoro-4-(Quinolin-8-Ylsulfonyl)But-2-En-1-Amine
- 英文名称(Z)-3-Fluoro-4-(Quinolin-8-Ylsulfonyl)But-2-En-1-Amine
- 中文名称(Z)-3-氟-4-(喹啉-8-基磺酰基)叔丁基-2-烯-1-胺
- IUPAC名称LOX-IN-3
- 其它别名2-Buten-1-Amine, 3-Fluoro-4-(8-Quinolinylsulfonyl)-, (2Z)-; (Z)-3-Fluoro-4-(Quinolin-8-Ylsulfonyl)But-2-En-1-Amine; (Z)-3-Fluoro-4-Quinolin-8-Ylsulfonylbut-2-En-1-Amine; Unii
- CAS编号2409963-83-1
- MFCD编号:MFCD34167539
- FDA UNII编号:DO94E28WYW
- 分子式:C13H13FN2O2S分子量:280.32
- 产品CID: 1186166
- 同类组份化合物CAS2409963-83-1 (free base)2409964-23-2 (HCl)
- 产品分类Inhibitors/Agonists → Metabolic Enzyme → LOX
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902200000-苯
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2025133663-A1
优先权日:2023-12-18
标 题:Digital tissue repair model
发明人：CASTEILLA LOUIS; PAUPERT-OUDJARI JENNY; PEURICHARD DIANE; LORSIGNOL ANNE; DEGOND PIERRE; OUSSET MARIELLE; PACARY ANASTASIA
权利人:INST NAT SANTE RECH MED; CENTRE NAT RECH SCIENT; UNIV TOULOUSE III – PAUL SABATIER; INSTITUT NATIONAL DE RECH EN INFORMATIQUE ET EN AUTOMATIQUE; UNIV SORBONNE; UNIV PARIS CITE
摘要:To understand the regeneration process, a digital agent-based model composed of segments and growing circles modelling ECM fibers and differentiating cells from adipose tissue respectively was developed5 to reproduce the tissue repair process and allowed the identification of key factors that control the emergence of tissue architecture. It integrated three critical parameters in ECM organization: frequency of fiber synthesis as well as the probability of cross-linking and unlinking. The inventors have identified the key biomechanical factors and developed a predictive model of tissue repair outcome for a subject and new therapeutic approach to drive tissue regeneration targeting ECM cross-linking, in particular, at 10 an early and transient stage after injury. The present disclosure relates to a method of predicting tissue repair outcome of an injured tissue in a subject in need thereof and therapeutic use of extracellular cross- linking fibers inhibitors for regenerative healing of injured tissues.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Yao Y, Findlay A, Stolp J, Rayner B, Ask K, Jarolimek W. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis. Int J Mol Sci. 2022 May 16;23(10):5533. doi: 10.3390/ijms23105533.
2: Vachhani P, Tan P, Watson AM, Wu SJ, Baker R, Cheung S, Lee SE, Chen CC, Chen TY, Hsiao HH, Lee JH, Masarova L, Tan SY, Baskar J, Charlton B, Findlay A, Hamprecht D, Jarolimek W, Leadbetter J, Miller J, Morgan K, Zahoor A, Hobbs G. A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis. Haematologica. 2025 Oct 1;110(10):2376-2387. doi: 10.3324/haematol.2024.287231. Epub 2025 Apr 17.
3: Chitty JL, Yam M, Perryman L, Parker AL, Skhinas JN, Setargew YFI, Mok ETY, Tran E, Grant RD, Latham SL, Pereira BA, Ritchie SC, Murphy KJ, Trpceski M, Findlay AD, Melenec P, Filipe EC, Nadalini A, Velayuthar S, Major G, Wyllie K, Papanicolaou M, Ratnaseelan S, Phillips PA, Sharbeen G, Youkhana J, Russo A, Blackwell A, Hastings JF, Lucas MC, Chambers CR, Reed DA, Stoehr J, Vennin C, Pidsley R, Zaratzian A, Da Silva AM, Tayao M, Charlton B, Herrmann D, Nobis M, Clark SJ, Biankin AV, Johns AL, Croucher DR, Nagrial A, Gill AJ, Grimmond SM; Australian Pancreatic Cancer Genome Initiative (APGI); Australian Pancreatic Cancer Matrix Atlas (APMA); Pajic M, Timpson P, Jarolimek W, Cox TR. A first-in- class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nat Cancer. 2023 Sep;4(9):1326-1344. doi: 10.1038/s43018-023-00614-y. Epub 2023 Aug 28.
📝 需求与反馈
尽可能描述清楚需求与问题信息
